Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-12-11
2004-05-04
Stockton, Laura L. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S546000, C514S556000, C514S561000, C548S339100, C560S196000, C562S507000
Reexamination Certificate
active
06730693
ABSTRACT:
The present invention relates to stable and non-hygroscopic double salts of fumaric acid (hereinbelow “double fumarates”) with a “carnitine”, wherein by “carnitine” either L-carnitine or isovaleryl L-carnitine are meant and an amino acid. The invention also relates to food supplements, dietary supplements, nutraceuticals and drugs containing said double fumarates.
Fumaric acid [(E)-2-butenedioic acid] exhibits interesting applications in both the nutritional and therapeutical field.
It is used as substitute for both tartaric acid which may bring about unpleasant gastrointestinal side effects due to its laxative effects, in the preparation of beverages and baking powders, and citric acid in fruit drinks.
The cardioprotective effect of fumaric acid has been assessed in the perfused rat heart (La Plante et al. “Effects and metabolism of fumarate in the perfused rat heart. A
13
C mass isotopomer study”, Am. J. Physiol. 272: E74-E82, 1997) and in the immature myocardium (Pearl et al. “Fumarate enriched blood cardioplegia results in complete functional recovery of immature myocardium” Ann. Thorac. Surg. 57: 1636-41, 1993).
Furthermore, fumaric acid is a “pharmacologically acceptable acid”: its salts are in fact encompassed in the list of “FDA-approved commercially marketed salts” published e.g. in the Journal of Pharmaceutical Sciences, Vol. 66, No. 1, (1977) pages 1-19.
Conversion of drugs to their respective pharmacologically acceptable salt forms is a widely utilized means for optimizing the administration forms or certain properties of the drugs, such as stability, hygroscopicity, flowability and the like.
Both L-carnitine acid fumarate and isovaleryl acid fumarate are known compounds. (Fumaric acid is a dicarboxylic acid: in the aforesaid acid fumarates only one of the two carboxylic groups is salified).
L-carnitine acid fumarate, whose preparation and physico-chemical properties are disclosed e.g. in U.S. Pat. No. 4,602,039, has been developed in order to overcome the complex problems of storage and processing due to L-carnitine inner salt hygroscopicity. L-carnitine acid fumarate is in fact very stable and, without provoking gastrointestinal side effects, shows a profile of humidity resistance even better than that of L-carnitine tartrate, a further non-hygroscopic salt which was also developed to overcome L-carnitine hygroscopicity.
The tartrate, however, has the advantage that both its carboxylic groups are salified with L-carnitine and consequently it contains a higher percentage in L-carnitine (68% vs. 58%).
Also isovaleryl L-carnitine acid fumarate, whose preparation is disclosed in the U.S. Pat. No. 5,227,518, is a stable compound endowed with considerable resistance to humidity.
Every endeavour made to salify also the free carboxylic group of acid fumarates wherein the other carboxylic group is salified with L-carnitine or isovaleryl L-carnitine has failed to-date. For instance, the attempt of preparing L-carnitine fumarate (i.e. the neutral salt which would have the advantage of a very high percentage in L-carnitine, about 73.5% vs. 68% in the tartrate and 58% in the acid fumarate) results in a highly hygroscopic substance which likely consists of a mixture of L-carnitine acid fumarate and L-carnitine inner salt. It is this latter which imparts high hygroscopicity to the end product as a whole.
Similar failures occur if the attempt is made to salify the free carboxylic group of acid fumarates with alkanoyl L-carnitines, such as acetyl and propionyl L-carnitines.
It is an object of the present invention to provide stable, non-hygroscopic double fumarates wherein one of the carboxylic groups of fumaric acid is salified with either L-carnitine or isovaleryl L-carnitine and the other carboxylic group is also salified with a compound endowed with useful nutritional, dietary or therapeutical properties.
It is, therefore, apparent that the utility of the salts of the present invention is to be found not only in their lack of hygroscopicity and high stability, but also insofar as both their cationic moieties contribute to the nutritional, energetic and/or therapeutic efficacy of the salt as a whole. The aforesaid efficacy of these novel salt is, therefore, not to be attributed exclusively to the “carnitine” moiety of the salt.
The aforesaid object is achieved by the double fumarates of L-carnitine or isovaleryl L-carnitine and an amino acid having the formula (I):
wherein: R is hydrogen or isovaleryl; and
[A+] is a positively charged amino acid selected from the group consisting of creatine, ornithine, lysine, arginine and hystidine.
The following compounds of formula (I) are to be considered specifically encompassed by the present invention:
L-carnitine and creatine fumarate;
isovaleryl L-carnitine and creatine fumarate;
L-carnitine and ornithine fumarate;
isovaleryl L-carnitine and ornithine fumarate;
L-carnitine and lysine fumarate;
isovaleryl L-carnitine and lysine fumarate;
L-carnitine and arginine fumarate;
isovaleryl L-carnitine and arginine fumarate;
L-carnitine and hystidine fumarate; and
isovaleryl L-carnitine and hystidine fumarate.
Lysine, arginine and hystidine are amino acids occurring in proteins, i.e. they are three out of the twenty amino acids which are obtained via controlled hydrolysis of naturally occurring proteins (see, e.g., J. David Rawn,
Biochemistry
, Chapter 3 “Amino acids and the primary structure of proteins”; McGraw-Hill, 1990).
Whilst in order to illustrate the nutritional and therapeutic efficacy of the amino acids in general reference is made to the conspicuously vast literature published to-date on this matter (see, e.g., F. Fidanza and G. Liguori,
Nutrizione umana
, Chapter 3: “Le proteine”, Casa Editrice Libraria Idelson, 1995; and I. Goldberg (Ed.),
Functional Foods
, Chapter 12, “Amino acids, peptides and proteins” Chapman & Hall, Inc. 1994), it is deemed useful to briefly address the topic of creatine and ornithine in view of their peculiar physiological role.
Creatine is an amino acid present in considerable amounts in the skeletal muscle tissue of vertebrates wherein about ⅔ thereof occurs as creatine phosphate.
Creatine is biosynthesized mainly in the liver and kidneys from three amino acids: glycine which provides the carbon skeleton, arginine which releases the amidino group and methionine which releases the methyl group. Creatine is excreted with urine as creatinine. Creatine can be taken with the diet since it is principally present in meat. However, in order to take 10 grams/day of creatine, 2.5 kg of meat should be eaten. The exogenous supply and endogenous biosynthesis must compensate for the daily turn-over of creatine to creatinine which in a 70-kg male subject can be estimated at about two grams.
The physiologic role of creatine is extremely important: principally in the skeletal muscle, but in the brain, liver and kidneys as well, creatine—by reversibly taking up ATP's phosphate groups—plays the role of reservoir of the energy-rich phosphate radicals. This reaction is critically important since ATP can not be stored in tissues in excess of a very limited threshold. It is creatine phosphate whose content in tissues is five times as much that of ATP, which provides for phosphate groups supply. Following a moderately wearying physical exertion, the creatine phosphate present in the skeletal muscle decreases in a far relevant amount than ATP does, thus showing that creatine phosphate rephosphorilates ADP as ATP becomes dephospharilated.
When the rate of ATP's metabolic production exceeds ATP's utilization, this results in creatine phosphate formation. Creatine phosphate is, therefore, a reservoir of immediately available energy, suitable for counterbalancing energy demands exceeding ATP's synthesis rate in metabolic phosphorylation processes.
Creatine is mainly taken by athletes and sportsman insofar as it increases the skeletal musculature if its intake is accompanied by lasting physical exertion. Creatine intake results in a lowering of fat while it enhances skeletal
Nixon & Vanderhye P.C.
Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
Stockton Laura L.
LandOfFree
Double salts of fumaric acid with a carnitine and an amino... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Double salts of fumaric acid with a carnitine and an amino..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Double salts of fumaric acid with a carnitine and an amino... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3261319